| Identification | Back Directory | [Name]
Esomeprazole potassium | [CAS]
161796-84-5 | [Synonyms]
Esomeprazole potassium
(S)-Omeprazole potassium
Esomeprazole potassium USP/EP/BP
(S)-5-methoxy-2-((4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl)-1H-benzo[d]
potassium,5-methoxy-2-[(S)-(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]benzimidazol-1-ide
(R)-5-METHOXY-2-((4-METHOXY-3,5-DIMETHYLPYRIDIN-2-YL)METHYLSULFINYL)BENZO[D]IMIDAZOL-1-IDE POTASSIUM SALT
6-Methoxy-2-[(S)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole potassium salt (1:1)
1H-Benzimidazole,6-methoxy-2-[(S)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-,potassium salt (1:1) | [EINECS(EC#)]
449-880-1 | [Molecular Formula]
C17H19KN3O3S | [MDL Number]
MFCD06797997 | [MOL File]
161796-84-5.mol | [Molecular Weight]
384.51 |
| Hazard Information | Back Directory | [Uses]
Esomeprazole potassium salt ((S)-Omeprazole potassium salt) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole potassium salt has the potential for symptomatic gastroesophageal reflux disease research[1][2][3]. | [in vivo]
Esomeprazole (30-300 mg/kg; oral gavage; daily; for 19 or 11 days; C57BL/6J mice) treatment significantly inhibits the progression of fibrosis throughout the lungs of the animals. Esomeprazole also reduces circulating markers of inflammation and fibrosis[2]. | Animal Model: | C57BL/6J mice (8-weeks old, 25-30 g) treated with cotton smoke-induced lung injury[2] | | Dosage: | 30 mg/kg, 300 mg/kg | | Administration: | Oral gavage; daily; for 19 or 11 days | | Result: | Significantly inhibited the progression of fibrosis throughout the lungs of the animals.
|
| [References]
[1] Wayne Goh, et al. Use of proton pump inhibitors as adjunct treatment for triple-negative breast cancers. An introductory study. J Pharm Pharm Sci. 2014;17(3):439-46. DOI:10.18433/j34608
[2] Christina Nelson, et al. Therapeutic Efficacy of Esomeprazole in Cotton Smoke-Induced Lung Injury Model. Front Pharmacol. 2017 Jan 26;8:16. DOI:10.3389/fphar.2017.00016
[3] Thomas J Johnson, et al. Esomeprazole: a clinical review. Am J Health Syst Pharm. 2002 Jul 15;59(14):1333-9. DOI:10.1093/ajhp/59.14.1333 |
|
| Company Name: |
Ralington Pharma
|
| Tel: |
+91-7948911722 +91-9687771722 |
| Website: |
www.ralingtonpharma.com |
|